Drugs.com - New Drug Approvals

Calquence Plus Chemoimmunotherapy Approved in the U.S. for Patients with Previously Untreated Mantle Cell Lymphoma

17 January 2025 -- AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible...

Feb 9, 2025 - 22:25
 0
Calquence Plus Chemoimmunotherapy Approved in the U.S. for Patients with Previously Untreated Mantle Cell Lymphoma
17 January 2025 -- AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible...
Read More

Tags:

Previous Article

FDA Approves Datroway (datopotamab deruxtecan-dlnk) for Patients with Previously...

Next Article

FDA Approves Lumakras (sotorasib) in Combination with Vectibix (panitumumab) for...

Related Posts

FDA Approves Steqeyma (ustekinumab-stba), a Biosimilar to Stelara

FDA Approves Steqeyma (ustekinumab-stba), a Biosimilar ...

Feb 9, 2025  0

FDA Approves Grafapex (treosulfan) Preparative Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

FDA Approves Grafapex (treosulfan) Preparative Regimen ...

Feb 9, 2025  0

FDA Approves Stoboclo (denosumab-bmwo), a Biosimilar to Prolia

FDA Approves Stoboclo (denosumab-bmwo), a Biosimilar to...

Mar 5, 2025  0